Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments

Table 1 Hepatitis B surface antigen-negative patients with either hepatitis B core or surface antibody or hepatitis B core/surface antibody positivity treated with tyrosine kinase inhibitors for hematological malignancies

Ref.	Type of disease, n	First-line TKI therapy	Patients, n	HBVr, n	Hepatitis, n	Liver failure, n
Orlandi et al[2]	CML	NS1	26	0	0	0
Sora et al[3]	CML	6 imatinib1, 4 nilotinib1	10	0	0	0
Wang et al[4]	CML	NS1	123	0	0	0
Innocenti et al[5]	CML	Ibrutinib2	108	2	0	0
Hammond et al[6]	CLL (15) MCL (4) WM (2)	Ibrutinib2	21	2	0	0
Chiu et al[7]	CCL (22) MCL (6)	12 ibrutinib2, 1 zanubrutinib2, 15 acalabrutinib2	28	2	2	2
Tsuruya et al[8]	CLL	Ibrutinib2	1	1	1	0
Lam et al[9]		Ibrutinib2	1	1	1	0

¹First-generation or second-generation tyrosine kinase inhibitors (imatinib and dasatinib/nilotinib, respectively) used alone or in combination.

²Bruton’s tyrosine kinase inhibitors.

³Patients with remote use of anti-hepatitis B virus therapy or anti-CD20 monoclonal antibodies were included in this study.

All studies reported in the table were retrospective. CML: Chronic myeloid leukemia; CLL: Chronic lymphocytic leukemia; HBVr: Hepatitis B virus reactivation; MCL: Mantle cell lymphoma; NS: Not significant; TKI: Tyrosine kinase inhibitors; WM: Waldenstrom macroglobulinemia.